884 patients near the time of peak concentrations during the highest dose administered. The drug was found to have linear kinetics over the dose range studied and a plasma half-life of 13.5 ± 2 hours. Plasma concentration-response curves indicate antiarrhythmic activity over all plasma concentrations, with 70% PVC reduction above 6.0 jg/ml. This study suggests that tocainide is a safe and effective antiarrhythmic agent during short-term administration and is worthy of further clinical trials.
SUMMARY Tocainide, a new oral antiarrhythmic agent, was studied in man in a short-term protocol designed to evaluate the efficacy, kinetics, and toxicity of this compound. Premature ventricular contractions (PVCs) were suppressed by >70% in 11 of 15 patients compared with pre-drug placebo controls. For these 11 responders, there was an average PVC reduction of 91% ± 10 (range 70 to 100%) at tocainide doses not associated with side effects. Mild transient central nervous system toxicity was observed in some ALL CURRENTLY AVAILABLE ANTIARRHYTH-MIC DRUGS have limited potential for widespread use on a long-term basis in man. With increasing recognition of the importance of treating cardiac arrhythmias, there is a need for oral antiarrhythmic agents which are more effective and less toxic, and which can be administered less frequently than those in current use.' One of the major disadvantages of available agents is their low therapeutic ratio combined with rapid elimination from the body, necessitating frequent drug administration. 4 This often requires that the patient be awakened from sleep to take the drug in order to maintain effective plasma concentration and avoid toxic side effects.
Tocainide (W36095), which has a chemical structure similar to lidocaine ( fig. 1 ), is orally effective and has marked antiarrhythmic activity in conscious dogs with ischemicallyinduced ventricular arrhythmias. 5 In a preliminary singledose study in a small group of human subjects, tocainide did not produce any toxic side effects and had a 12-to 15-hour elimination half-life.
Based on these preliminary observations, the study described in this paper was designed to determine the efficacy and safety of tocainide for treating patients with stable ventricular arrhythmias, and to establish the relationship between tocainide dose and plasma concentration. In addition, the use of a computer-based system for quantitation of the frequency of premature ventricular contractions (PVCs) permitted analysis of the relationship between the plasma concentration of tocainide and its antiarrhythmic effect.
Methods
Fifteen patients (ten men and five women) with frequent PVCs were studied. The average age of the patients was 56 years (range 37 to 68 years), and the underlying heart dis-ease was coronary artery disease in seven patients, mitral valve prolapse in three, cardiomyopathy in one, and no apparent evidence of heart disease other than PVCs in four.
All antiarrhythmic drugs were discontinued at least five half-lives before entering this study, with two exceptions. One patient requiring propranolol for angina pectoris, and one patient who had previously developed sustained ventricular tachycardia when quinidine was discontinued, were treated with a constant dosage regime of these drugs throughout the entire period of the study. Patients with renal disease, hepatic disease, seizure disorders, uncompensated heart failure, or advanced degrees of heart block, were excluded. During the study normal food intake was permitted, including a light breakfast the morning of blood sampling.
Protocol Design
The protocol design for our study is summarized in figure 2. The study was an 8-day, single-blind program carried out in the Stanford General Clinical Research Center. Protocol days 1 and 2 were a pre-drug placebo control period. On days 2, 3, and 4, 400 mg of tocainide were administered every 8 hours, with an extra 400 mg dose after four hours on day 2. After achieving plasma concentrations of tocainide predicted on the bases of preliminary single dose studies to be at steady-state, the drug dose was increased to 600 mg every 8 hours. This dose was continued until new, predicted steady-state plasma concentrations were obtained on day 6. In order for each patient to serve as his own control, a final post-drug placebo period was instituted on days 6, 7, and 8.
Blood samples for tocainide determination were obtained via indwelling heparin lock at 0, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, and 8.0 hours after the final dose at each level, and serially for 56 hours after the final dose of tocainide. A blank urine specimen before tocainide administration and the total amount of urine passed during the final dosage interval at both dose levels were collected for each patient. An aliquot of this urine was used to determine the amount of tocainide excreted unchanged during one dosage interval at steadystate. Tocainide plasma and urine concentrations were measured by a high-pressure liquid chromatographic method. 6 Calibration curves were prepared for each set samples by adding known amounts of tocainide and internal standard to control plasma and urine. These curves were linear in the range of 0.1-5.0 ,ug and had an average coefficient of variation of 2%. No peaks which interfered with those of tocainide or the internal standard have been observed in urine or plasma. All patients were ambulatory and were encouraged to maintain similar activity levels during each day of the protocol. Continuous electrocardiograms were recorded on magnetic tape with an Avionics ambulatory electrocardiogram recorder during the entire protocol. Before entering the study, patients were told they would be receiving either drug or placebo at various times during the week, and that during the study a variety of tests and blood samples would be obtained. The nature of the drug and potential risks were explained and each patient signed written informed consent documents. Hematologic, renal, and hepatic safety tests, 12-lead electrocardiograms, and chest X-rays were obtained frequently during the study.
Data Analysis
Ambulatory electrocardiogram tapes were processed using a computer system which counts all PVCs on the tape.7 An estimate of the accuracy of PVC count for each patient is provided in the Appendix. Antiarrhythmic efficacy was evaluated from four 8-hour periods: the final 8-hour dose interval during the pre-drug placebo control period, the final 8-hour dose interval at steady-state on 400 mg and 600 mg doses of tocainide, and the final 8-hour dose interval during the post-drug placebo control period. The total number of PVCs in each of the latter three 8-hour intervals, determined as the average number of PVCs per 15 minutes, was expressed as the percent change from the total number in the initial pre-drug placebo control 8-hour interval. Drug responders were defined as those patients exhibiting a 70% or greater reduction in PVCs over the 8-hour dose interval compared with the pre-drug placebo dose interval.
The mean steady-state tocainide plasma concentration was obtained by dividing the area under the plasma tocainide concentration-time curve for a dosage interval by the dosage interval. The plasma half-life was determined by fitting concentration time-data from 8 to 56 hours after the final drug dose using a log-linear least-squares method. All average data are given as the mean ± standard deviation, The plasma concentration-antiarrhythmic response curve was constructed in the following manner: During the final 400 mg dose interval and during the plasma level decay for 56 hours after the final 600 mg dose, the PVC frequency during sequential 4-hour periods was determined and expressed as a percent of the number of PVCs in the final post-drug placebo control period. The average plasma tocainide concentration during each 4-hour interval was also determined. A group concentration-response curve was obtained for the drug responders by averaging the percent PVC reduction at various plasma concentrations and plotting these values versus the log mean plasma concentrations.
Results

Pharmacokinetics
The average tocainide concentrations at the start and end of the final dosing interval for the 400 mg dose regimen were 5.65 ± 1.24 and 5.76 ± 1.15 ,ug/ml, respectively. Corresponding values for the 600 mg dose regimen were 8.00 ± 1.67 and 8.03 ± 1.66 mug/ml. These pairs of values were not significantly different, indicating that steady-state plasma concentrations of tocainide had been reached for each dosage regimen. This is consistent with the mean halflife of 13.5 hours (table 1) . Division of the average mean steady-state tocainide concentrations for the 400 mg and 600 mg dose regimens by the dose (table 1) indicates that tocainide has linear kinetics over the limited range of doses examined ( fig. 3 ). For an oral dosing interval of 8 hours, a mean steady-state plasma concentration of 1.7 ,ug/ml is obtained for every 100 mg of tocainide administered. Similarly, the average peak plasma concentration is 2.3 uggml for every 100 mg of tocainide taken orally every 8 hours ( fig. 3 ). This peak plasma concentration occurred 1. 3 . 4 ), and increasing the dose to 600 mg provided a modest further PVC suppression. Three patients demonstrated 70% or greater PVC suppression only at the 600 mg dose. The maximum PVC reduction achieved without side effects in the 11 responders was 91 ± 10% (range 70 to 100%). This occurred on the 400 mg dose in six patients, and on the 600 mg dose in five patients.
The PVCs returned toward or above initial pre-drug control frequencies during the final 8-hour post-drug placebo control period in 10 of the 11 patients whose PVCs were suppressed by tocainide. The single patient with an insignificant number of PVCs during the final control period demonstrated a return of PVCs to control levels late in protocol day 6 and during all of day 7, but for unexplained reasons had almost no PVCs during the 8-hour period chosen for the post-drug control period on day 8. As illustrated in figure 4 , there was a wide range of PVC frequencies during this final control period, ranging from -100 to +259% change from the pre-drug PVC frequency. However, for the group as a whole, the average post-drug PVC frequency was 80% of the initial pre-drug frequency.
The tocainide plasma concentration-antiarrhythmic response curve for the group of 11 responders is shown in figure 5 . The curve demonstrates continuous antiarrhythmic activity over the range of plasma concentrations studied.
The mean average steady-state plasma tocainide concentrations in the four patients whose PVCs were not suppressed by tocainide were 6.27 ± 1.95 for the low dose of tocainide, and 10.15 ± 1.82 for the high dose. The corresponding values for the patients responding to tocainide were 7.15 ± 1.45 and 10.21 ± 1.86. The differences between these groups for each dose were not statistically significant.
Examination of the case histories and diagnoses of these patients, together with their ambulatory electrocardiograms, offered no insight as to why these patients failed to respond to tocainide.
Side Effects
Two patients experienced mild symptoms during the 400 mg dosing period. One who experienced transient dizziness on the mornings of protocol days 3 and 4 had similar, but more severe, symptoms on the morning of day 2 while on placebo. The other experienced transient dizziness and pressed by >70%. The four periods on the horizontal axis correspond to the shaded areas infigure 2, and the vertical axis represents the percent change in total number ofPVCs over the 8-hour dose interval compared to the 8-hour pre-drug placebo control period. It can be seen that in eight patients, PVCs were suppressed by >70% with 400 mg of tocainide every 8 hours compared to the pre-drug control period, and the 600 mg dose usually provided only a modest further reduction in PVCs. Three patients' PVCs were suppressed by >70% only on the 600 mg dose. The dotted lines represent patients who did not complete the 600 mg dose period, or were maintained on the 400 mg dose duringprotocol days 4, 5, and 6. The data points on the right represent the return of PVCs during the post-drug placebo period. blurred vision after two doses on protocol day 3. The latter patient was maintained on the 400 mg dose through day 6 of the protocol without a recurrence of the symptoms.
Seven patients experienced mild symptoms on the 600 mg dose regimen. One patient experienced a tremor of the hands two hours after the third 600 mg dose, and no further drug doses were given. Plasma concentrations (Cp) of about 11.0 Ag/ml were measured at the time the tremor stopped.
Another had diplopia, unsteady gait, and vertigo one to two hours after the first 600 mg dose and was maintained for the duration of the study without symptoms on 400 mg doses. It is estimated that plasma concentrations were in the range of 11 gg/ml in this patient when these symptoms occurred. One patient had mild nausea and slight incoordination of the hands during day 5 but not on day 6, while receiving the same dosage regimen. A peak plasma concentration at steady-state (Cp89 max) of 12.0 ,ug/ml was measured for this patient on day 6. A patient who had a Cp8s max of 16.3 ,ug/ml felt slight dizziness and nausea during three of the six 600 mg doses. This patient reported similar symptoms on day 2 while on placebo. Another patient, who had a Cp88 max of 13 ,g/ml reported nausea and blurred vision persisting throughout three of the six 600 mg doses. One patient who also had a Cp88 max of 13 ,ug/ml was anxious during days 4 to 6 and reported right leg numbness 51/2hours after the last dose on day 6. The seventh patient noted slight incoordination of the hands on day 6, at a time when Cp was 13.3 ,g/ml. Seven patients experienced no toxicity during the entire protocol, and three of these patients had plasma concentrations in the range of 16.0 to 18.8 ,ug/ml. From the toxicity data provided by this study, it would appear that there is wide intersubject variability in the relationship between plasma concentration and the various manifestations of toxicity.
Safety Testing
There were no abnormalities detected on the serial laboratory screening tests, and there was no consistent effect on the cardiac conduction system as measured by the P-R interval and QRS duration on the electrocardiogram. No patient demonstrated clinical or radiologic evidence of myocardial depression.
Discussion
The value of pharmacokinetic and pharmacodynamic studies in early clinical trials was emphasized recently by the Seventh Bethesda Conference of the American College of Cardiology on the development and introduction of new cardiovascular drugs.8 Our study was carefully designed to yield such information and to minimize or eliminate factors which could bias its outcome. The ambulatory hospital setting was chosen to simulate everyday activities as closely as possible while still ensuring relatively uniform activity level throughout the study, and thus minimize the influence of changes in activity on PVC frequency. This setting also ensured patient compliance and permitted collection of accurate pharmacokinetic data. The post-drug placebo period was incorporated to exclude the possibility that arrhythmia reduction during drug administration was caused by the hospitalization itself. The return of PVCs during the post-drug control period suggests that the arrhythmia reduction was indeed due to drug administration.
The single-blind design with placebo administration during control periods precludes a reduction in PVC frequency resulting from the psychological effects of taking a new antiarrhythmic agent. A double-blind design was not utilized, in order to provide maximum patient safety in this early study of the effects of tocainide in patients with cardiac disease. The need for a double-blind protocol is minimal when using an objective response, namely, reduction of PVC frequency which can be precisely quantitated as the measure of drug action. The single-blind design may have influenced the evaluation of side effects; every effort was made, however, to evaluate objectively and record accurately all patient symptoms during this study.
Quantitative analysis of PVC frequency on a large number of ambulatory electrocardiogram tapes has demonstrated that PVC frequency in any given patient can be highly variable, with wide spontaneous fluctuations in any given individual.9 This spontaneous variability, as demonstrated in this study by the differences in PVC frequency from preto post-drug placebo control periods, may obscure accurate determination of a plasma concentration-antiarrhythmic effect relationship for a given individual patient, unless large numbers of data are analyzed, as was done in this study.
Construction of a plasma concentration response curve requires reconsideration of the meaning of a therapeutic plasma concentration. The antiarrhythmic effect of tocainide is not an all-or-none phenomenon, but is continuous over a range of plasma concentrations. The plasma tocainide concentration-antiarrhythmic response curve shown in figure 5 indicates that, for the group of responders, 70% PVC suppression was achieved when the plasma concentration was above 6 ug/ml, with 90% PVC suppression achieved at plasma concentration above 10,ug/ml. It should be noted that, while the concentration-response curve shown in figure 5 is indicative of the percent reduction in PVC frequency which is expected at a given concentration for the whole group, its slope is more shallow than the concentra-887 VOL 54, No 6, DECEMBER 1976 tion-response curve for an individual patient.'0 The group data may be used to provide an estimate of the plasma concentration range over which one may expect antiarrhythmic response to tocainide. However, a consideration of each individual patient's response is required to establish the most appropriate dosage regimens for that patient. Detailed analysis of the concentration-response curves for each responder and their use in devising individualized dosing regimens is beyond the scope of this discussion and will be presented elsewhere. The therapeutic ratio for a drug is generally defined as the ratio of the toxic plasma concentration to the concentration required to produce a therapeutic effect. The clinical importance of this ratio is critically linked to drug kinetics and dosage regimen, which determine the range over which plasma concentration varies. For instance, with an intravenous infusion at steady-state, there will be no fluctuation in plasma concentration, and effective drug concentrations may be achieved without toxicity despite a small therapeutic ratio. Administering the same total daily dose orally in divided doses may result in fluctuations in plasma concentrations which will periodically exceed the toxic concentration. This is especially true for infrequent dosing with drugs which are rapidly eliminated from the body. Drugs with slower elimination, such as tocainide, may be administered relatively infrequently without toxicity because the slow elimination minimizes the fluctuation in plasma concentration. The moderate incidence of side effects associated with the 600 mg dose suggests that, despite the average 13.5-hour half-life of this drug, some patients receiving this regimen will require dosing every 8 hours for continuous maintenance of therapeutic plasma concentrations and in order to avoid peaks which may cause transient minor symptoms. It would be expected, however, that many other patients may tolerate, and have their arrhythmias controlled with, a 12-hour dose interval. Either an 8 or 12-hour dose interval would provide a more convenient regimen than is possible with currently available antiarrhythmic agents.
Because of the nature of the plasma concentrationresponse relationship, a disproportionate increase in plasma drug concentration is required to increase response in the range of 80 to 100%, compared with that required to increase response in the range of 50 to 70%. This fact must be taken into account when attempting to adjust doses to reduce PVC frequency to near zero. Almost all toxicity was encountered in patients taking the 600 mg dose, but subsequent analysis of the data indicated that marked PVC suppression had been achieved in these patients on the 400 mg dose. This information was unavailable at the time of the study since electrocardiogram tapes, other than the initial pre-drug control tape, were not processed until after a patient had completed the study so that the unblinded physician would not be biased.
In this study of patients with cardiac disease, plasma concentrations of tocainide HCI, after oral dosing, were adequately described by a one-compartment open model and showed linear kinetics over the two doses examined. The estimates of pharmacokinetic parameters and antiarrhythmic efficacy found in this study are in close agreement with those found by Lalka et al." and by the Vanderbilt group.'2. 13 Although the range of doses in our study was relatively narrow, Lalka found linear kinetics following oral doses of 10 to 1000 mg. It is of interest that the group studied by Lalka was comprised of normal volunteers who averaged 30 years of age. The patients in our study averaged 56 years of age and are more likely to be representative of the patient population in which the drug may be used. Age and diseaserelated differences in pharmacokinetic parameters between patients and normal volunteers have been reported for some other drugs.'4 " Although no differences in the kinetics of tocainide were observed between patients in this study and normals, it should be noted that the present protocol excluded patients with renal or hepatic disease and uncompensated heart failure. This finding should, therefore, not be extrapolated to other patient subgroups not included in this study.
Although tocainide and lidocaine have structural similarities, tocainide appears to be suitable for oral administration whereas lidocaine is not. The difference relates to dissimilarities in kinetics of disposition for the two drugs. Lidocaine has a clearance of 720 ml/min'6 and a high hepatic extraction ratio resulting in a low systemic bioavailability following oral dosing.'7 On the other hand, tocainide has a nonrenal, presumably hepatic, clearance of 102 ml/min" which is consistent with its high systemic bioavailability following oral dosing. This difference may result from the fact that tocainide is a primary amine and does not undergo N deethylation, the initial step in the metabolism of lidocaine.
A potentially important characteristic of the kinetics of this drug is the small degree of intersubject variability in the average steady-state concentrations; the average coefficient of variation for the two dose levels was 19.1%. The corresponding value for the maximum plasma concentration was 21.2%. This implies that for many patients without renal or hepatic disease or uncompensated heart failure, individual steady-state tocainide plasma concentrations can be reliably predicted on the basis of dose. However, for some patients plasma tocainide concentration measurements may help to adjust the dose. The drug's linear kinetics make dose adjustment relatively simple once an individual's kinetic parameters are known. In practice, the calculation of the new dose is most conveniently made by: new dose = old dos, Cp (desired)
Cp (measured)
where Cp (desired) and Cp (measured), respectively, are the desired and measured average plasma concentration at steady-state. For tocainide, Cp (measured) could be estimated with a single determination at the midpoint of the dosage interval 48 hours or more after the initiation of therapy.
In a study determining effectiveness for suppressing PVCs, procainamide and quinidine were each successful in only one-third of the patients studied despite the fact that the doses used were associated with toxicity in a high proportion of patients.3 Even when procainamide is successful in eliminating arrhythmias, long-term administration is associated with a high incidence of a lupus-like reaction,'8 1' which necessitates discontinuing the drug. To determine whether or not tocainide is superior to these agents will require studies in large numbers of patients. In the present study, tocainide continuously suppressed PVCs by an average of 91 % in 11 of 15 patients at doses not causing side effects CIRCULATION TOCAINIDE/Winkle et al.
when administered on an 8-hour dose schedule. In another short-term efficacy study, Woosley'3 reported that seven of ten patients demonstrated PVC suppression on tocainide without serious side effects. However, in our study plasma concentrations only slightly higher than those associated with antiarrhythmic effect were associated with a moderate incidence of transient central nervous system toxicity. The importance of these side effects during long-term therapy is unknown. The limited experience gained during these studies indicates that tocainide is an antiarrhythmic agent worthy of further clinical trials. The information reported here should provide a rational basis for dosing in such trials.
